AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

89bio Inc. (ETNB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.96

-0.34 (-3.01%)

At close: Feb 20, 2025, 3:59 PM

11.17

1.87%

After-hours: Feb 20, 2025, 05:03 PM EST

undefined% (undefined)

Bid	10.6
Market Cap	1.60B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.96
PE Ratio (ttm)	-3.7
Forward PE	n/a
Analyst	Buy

Ask	11.3
Volume	633,098
Avg. Volume (20D)	2,065,376
Open	11.19
Previous Close	11.30
Day's Range	10.85 - 11.28
52-Week Range	5.99 - 16.63
Beta	undefined

About ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorpor...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 11, 2019

Employees 70

Stock Exchange NASDAQ

Ticker Symbol ETNB

Website https://www.89bio.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for ETNB stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 173.60% from the latest price.

Buy 77.78%

Hold 11.11%

Sell 0.00%

Stock Forecasts

Next Earnings Release

89bio Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+15.72%

89bio shares are trading higher after Wolfe Resear... Unlock content with Pro Subscription

3 weeks ago

+26.23%

89bio shares are trading lower after the company announced it proposed a $250 million public offering of common stock and pre-funded warrants.

News

1 day ago · zacks.com

Should You Buy 89BIO (ETNB) After Golden Cross?

89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200-day si...

1 day ago · zacks.com

Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positiv...

1 week ago · 247wallst.com

Insider Buying Surges in February, Especially in These 6 Stocks

In January, the number of notable insider purchases was somewhat muted.

2 weeks ago · zacks.com

Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positiv...

3 weeks ago · seekingalpha.com

89bio's Pegozafermin Is Now Gaining Momentum

3 weeks ago · fool.com

Why 89bio Stock Lagged the Market Today

89bio (ETNB 0.11%) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new sto...

1 month ago · seekingalpha.com

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 E...

1 month ago · zacks.com

New Strong Sell Stocks for January 7th

ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.

2 months ago · zacks.com

New Strong Sell Stocks for November 16th

CLF, ETNB and HZO have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2024.